Teglutik
E561110
Teglutik is an oral liquid formulation of the drug riluzole used to slow disease progression in patients with amyotrophic lateral sclerosis (ALS).
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
brand name medication
ⓘ
pharmaceutical drug ⓘ |
| bioequivalence | bioequivalent to riluzole tablets in systemic exposure ⓘ |
| commonAdverseEffect |
abdominal pain
ⓘ
dizziness ⓘ elevated liver enzymes ⓘ fatigue ⓘ nausea ⓘ vomiting ⓘ |
| containsExcipient |
glycerol
ⓘ
sodium benzoate ⓘ sorbitol ⓘ |
| containsSubstance | riluzole NERFINISHED ⓘ |
| contraindication | severe hepatic impairment ⓘ |
| dosingSchedule | twice daily ⓘ |
| drugInteraction |
CYP1A2 inducers
ⓘ
CYP1A2 inhibitors ⓘ |
| eliminationRoute | renal excretion of metabolites ⓘ |
| hasActiveIngredient | riluzole NERFINISHED ⓘ |
| hasAdministrationDevice | oral dosing syringe ⓘ |
| hasAdvantage | facilitates dosing in patients with swallowing difficulties ⓘ |
| hasATCCode | N07XX02 ⓘ |
| hasDosageForm |
oral liquid
ⓘ
oral suspension ⓘ |
| hasStrength |
5 mg/mL
ⓘ
50 mg/10 mL ⓘ |
| indicatedFor | adult patients with amyotrophic lateral sclerosis ⓘ |
| mechanismOfAction |
blocks voltage-dependent sodium channels
ⓘ
inhibits glutamate release ⓘ interferes with excitatory neurotransmission ⓘ |
| metabolism | extensively metabolized in the liver ⓘ |
| overdoseEffect | may cause acute toxicity including neurologic symptoms ⓘ |
| pharmacologicalClass | glutamate release inhibitor ⓘ |
| pregnancyCategory | use only if potential benefit justifies potential risk ⓘ |
| primaryMetabolizingEnzyme | CYP1A2 NERFINISHED ⓘ |
| regulatoryStatus | prescription only ⓘ |
| requiresMonitoring | liver function tests ⓘ |
| routeOfAdministration | oral ⓘ |
| storageCondition | store at controlled room temperature ⓘ |
| takenWith | water ⓘ |
| targetsDiseaseProcess | motor neuron degeneration in ALS ⓘ |
| therapeuticArea | neurology ⓘ |
| therapeuticEffect | slows disease progression in ALS ⓘ |
| treats |
ALS
NERFINISHED
ⓘ
amyotrophic lateral sclerosis ⓘ |
| usedAs | disease-modifying therapy in ALS ⓘ |
| warning | risk of liver injury ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Riluzole